Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus CHLORMERODRIN HG 197.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus CHLORMERODRIN HG 197.
AN-DTPA vs CHLORMERODRIN HG 197
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
Radioactive mercury isotope that emits gamma rays; distributes in renal parenchyma, allowing scintigraphic imaging of kidneys. The mercury moiety binds to sulfhydryl groups in renal tubules, concentrating in functioning renal tissue.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
Chlormerodrin Hg 197 is administered intravenously as a single dose of 10 µCi (0.37 MBq) for renal imaging. The typical adult dose is 10-30 µCi (0.37-1.11 MBq) IV.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life approximately 3 days (72 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Renal: >90% of absorbed dose excreted in urine within 24 hours; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical